MyMSTeam

What are the statistics and risks of developing PML with MS medications?

The risk of developing PML varies significantly based on whether you have JC virus antibodies and which MS medication you're taking.

JC Virus Antibody Status Matters:

If you test negative for JC virus antibodies, your risk of developing PML is much Show Full Answer

What are the statistics and risks of developing PML with MS medications?

The risk of developing PML varies significantly based on whether you have JC virus antibodies and which MS medication you're taking.

JC Virus Antibody Status Matters:

If you test negative for JC virus antibodies, your risk of developing PML is much lower. However, if you test positive, the risk increases, especially with higher antibody levels in your blood.

Medications Associated with PML Risk:

Natalizumab (Tysabri) is considered the medication with the highest PML risk. Cases have also been reported with:
- Dimethyl fumarate (Tecfidera)
- Fingolimod (Gilenya)
- Rituximab (Rituxan)

Risk Management:

Doctors typically monitor JC virus antibody levels every six months if you're taking immune-suppressing medications. Higher antibody levels indicate increased PML risk.

Some neurologists recommend staying on natalizumab for up to two years before switching to another treatment, while carefully monitoring for PML throughout.

The decision to take these medications often comes down to weighing the risk of PML against the risk of MS relapses causing permanent damage. Many people find that with careful monitoring, the benefits outweigh the risks.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

The Emotional Impact of MS Treatment Decisions

JC Virus, PML, and Multiple Sclerosis